May 11, 2020 / 12:25 PM / 14 days ago

BRIEF-Protalix Biotherapeutics Reports Positive Topline Results From Trial Evaluating Pegunigalsidase Alfa For Treatment Of Fabry Disease

May 11 (Reuters) - Protalix Biotherapeutics Inc:

* PROTALIX BIOTHERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE BRIDGE PHASE III OPEN-LABEL, SWITCH-OVER CLINICAL TRIAL EVALUATING PEGUNIGALSIDASE ALFA FOR THE TREATMENT OF FABRY DISEASE

* PROTALIX BIOTHERAPEUTICS INC - PHASE III BRIDGE OPEN-LABEL, SWITCH-OVER CLINICAL TRIAL MET MAIN OBJECTIVES FOR SAFETY AND EFFICACY

* PROTALIX BIOTHERAPEUTICS INC - TOPLINE ANALYSIS INDICATES SUBSTANTIAL IMPROVEMENT IN RENAL FUNCTION

* PROTALIX BIOTHERAPEUTICS INC - PRX-102 WAS FOUND TO BE WELL TOLERATED

* PROTALIX BIOTHERAPEUTICS INC - HAVE EXPERIENCED MINOR DELAYS IN COMPLETING BLA SUBMISSION FOR PRX-102 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below